TRPML1 agonist ML-SA1 could increase Ca2+ spark frequency in myocardial infarction (MI) CMs (Fig. 6A and C), which could be eliminated by SR RyR2 inhibition (Fig. 6B). This evidence concerns the gene RYR2 and myocardial infarction.